New Drug Combination for Ovarian and Primary Peritoneal Cancers
Name of the Trial
Why This Trial Is Important
Systemic chemotherapy with a platinum-containing drug, such as cisplatin or carboplatin, is a commonly used treatment for advanced ovarian epithelial cancer. Although this type of treatment frequently results in tumor shrinkage, most patients ultimately become resistant to platinum-based chemotherapy.
In this trial, women with ovarian epithelial or primary peritoneal cancer whose disease has relapsed less than 6 months after treatment with initial chemotherapy will receive cisplatin and a drug called flavopiridol. Flavopiridol blocks the activity of a number of proteins that help cancer cells grow and spread, and it may also make cancer cells more sensitive to cisplatin.
"Women with platinum-resistant ovarian cancer have very few effective treatment options," said Dr. Bible. "Our laboratory studies have shown that flavopiridol can increase the platinum concentrations in cells when administered with cisplatin, and we believe that this may lead to a reversal of platinum resistance.""An early analysis of patients currently on the trial has revealed a better than expected response rate, including one patient with a complete remission," he added.
Who Can Join This Trial
Study Site and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.